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Purpose
Dehydroepiandrosterone (DHEA) and its sulfated deriva-
tive DHEA-S are endogenous hormones secreted by the
adrenal cortex in response to ACTH and stress. Levels of
DHEA and DHEA-S are decreased with advancing age
and depression. Trials of DHEA for mid-life depression
have shown promising yet inconclusive results, due in part
to small sample sizes and lack of placebo comparators. An
additional concern, with the risk of breast cancer in this
age group, is the high doses of DHEA supplementation
used. We present a case in which low-dose topical DHEA
and other hormonal agents were used as an adjunct to
conventional antidepressant therapy to target symptoms
of depression and fatigue in a peri-menopausal woman.
Methods
Baseline levels of DHEA-S were collected. In addition, we
assessed fatigue and depression using PROMIS measures
and vitality based on the SF-36. DHEA/Pregnenolone/
Progesterone topical cream, dosed at 10/20/50 mg/mL
per day, was added to the patient’s usual treatment regi-
men of fluoxetine 20mg daily.
Results
Baseline labs revealed DHEA-S level of 63 (ref range: 15-
170). Baseline questionnaires revealed fatigue at 25/35
(moderate-severe), depression at 23/40 (moderate), and
vitality at 8/24 (low). After 12 months of treatment,
DHEA-S was slightly increased at 83 and rating scores
included fatigue at 11 (mild), depression 10 (mild) and
vitality at 19 (high). A decrease of fluoxetine to 10 mg
daily was well tolerated and no adverse effects were seen
with treatment.
Conclusion
Given its safety and efficacy profile, low-dose topical
DHEA adjunctive treatment for fatigue and depression in
mid-life may result in well-tolerated improvements in
subjective measures of fatigue, depression, and vitality,
and warrants further investigation. Future investigation
in a placebo-controlled, RCT is warranted. Such studies
should assess safety and tolerability, effect on down-
stream hormones such as estradiol, optimal dosing, and
impact on mood.
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